Immunotherapy in Melanoma | Specialty

Ovarian Cancer: Testing for Mutations

November 20th 2017

Molecular Testing in Ovarian Cancer

November 20th 2017

Dr. Postow on Entrectinib in Melanoma

November 15th 2017

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Neoadjuvant Nivolumab/Ipilimumab Combo Effective but Toxic for Melanoma

November 12th 2017

Neoadjuvant nivolumab plus ipilimumab demonstrated almost a tripling in objective response rate compared with the PD-1 inhibitor alone but at the cost of significant added grade 3 adverse events for patients with high-risk resectable melanoma.

NKTR-214/Nivolumab Combination Shows Promise in Early Study

November 12th 2017

The combination of the CD122-biased cytokine NKTR-214 and the PD-1 inhibitor nivolumab demonstrated target lesion reductions of 72% for patients with advanced cancers.

Dr. Soyer Discusses Screening for Melanoma

November 10th 2017

Peter Soyer, MD, academic dermatologist, professor, The University of Queensland Diamantina Institute, discusses screening for melanoma.

Dr. Luke on the Future Role of Immunotherapy Combinations in Melanoma

November 10th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the future of immunotherapy combinations for patients with melanoma.

Dr. Weber on the Toxicity Profile of Nivolumab Versus Ipilimumab for Melanoma

November 9th 2017

Jeffrey S. Weber, MD, PhD, deputy director and co-director of the Melanoma Program at the Laura and Isaac Perlmutter Cancer Center at NYU Langone Medical Center, discusses the toxicity profile seen with nivolumab versus ipilimumab for patients with melanoma.

New Adjuvant Therapy Era Builds in Melanoma

November 6th 2017

Researchers are seeking to determine whether the plethora of new therapies that have been introduced in recent years in the advanced and metastatic settings can benefit patients at risk of recurrence earlier in the treatment timeline for melanoma.

BRAF/MEK Combinations Continue to Revolutionize Melanoma Landscape

November 1st 2017

Michael A. Postow, MD, discusses the impressive efficacy seen with combining BRAF and MEK inhibitors for patients with melanoma.

Dr. Saw Discusses Study of Vitamin D in Melanoma

October 31st 2017

Robyn Saw, FRACS, MS, MBBS, associate professor of surgery, The University of Sydney, discusses a study of vitamin D in melanoma.

Dr. Luke on the Combination of Pembrolizumab and T-VEC for Melanoma

October 28th 2017

Jason Luke, MD, assistant professor of medicine at the University of Chicago Medicine, discusses the combination of pembrolizumab (Keytruda) and talimogene laherparepvec (T-VEC; Imlygic) for the treatment of patients with melanoma.

Glembatumumab Vedotin Induces 61% DCR in Uveal Melanoma

October 27th 2017

Glembatumumab vedotin (CDX-011) induced a disease control rate of 61% in patients with metastatic uveal melanoma, despite a low a low objective response rate of 6%.

Dr. Guitera on the RADICAL Trial for Melanoma

October 25th 2017

Pascale Guitera, MD, director, Sydney Melanoma Diagnostic Centre, associate professor, the University of Sydney, discusses the RADICAL trial of patients with melanoma.

Dr. Schaider Discusses Drug Resistance for Melanoma

October 25th 2017

Helmut Schaider, MD, associate professor, Dermatology Research Centre, the University of Queensland, discusses adaptive drug resistance for patients with melanoma.

Dr. Lebbe Discusses Efficacy of Avelumab in Merkel Cell Carcinoma

October 23rd 2017

Celeste Lebbe, MD, PhD, Hopital Saint Louis in Paris, discusses the efficacy of avelumab (Bavencio) in patients with stage IV Merkel cell carcinoma.

FDA Grants Adjuvant Dabrafenib/Trametinib Breakthrough Designation for BRAF+ Melanoma

October 23rd 2017

The FDA has awarded the combination of dabrafenib (Tafinlar) and trametinib (Mekinist) a breakthrough therapy designation for the adjuvant treatment of patients with stage III melanoma with a BRAF V600 mutation following complete resection.

Adjuvant Nivolumab/Ipilimumab Sustains RFS Benefit in Melanoma at 3 Years

October 22nd 2017

The combination of adjuvant nivolumab and ipilimumab led to a 3-year relapse-free survival rate of 71% in patients with high-risk resected stage IIIC/IV melanoma.

Adjuvant Dabrafenib/Trametinib RFS Benefit Persists Across Melanoma Subgroups

October 21st 2017

A doubling in 3-year relapse-free survival rates remained consistent across patient subgroups treated with dabrafenib and trametinib, when compared with placebo, for patients with BRAF-mutant stage III melanoma.

Dr. Amaria on Genetically Modified TILs in Melanoma

October 21st 2017

Rodabe N. Amaria, MD, department of Melanoma Oncology, division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, discusses using genetically modified tumor infiltrating lymphocytes (TILs) in patients with advanced melanoma.